Maternal outcomes following introduction of antiretroviral therapy in the public sector: A prospective study at a tertiary hospital in the Eastern Cape

South African Journal of Obstetrics and Gynaecology

Volumn 15, Issue 1, 2009, Pages 26-33

  Bera, Ebrahim ^a,b  

^a WALTER SISULU UNIVERSITY   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; DELIVERY; DRUG FATALITY; FEMALE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFANT; LACTIC ACIDOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MATERNAL MORBIDITY; MATERNAL MORTALITY; PATIENT COMPLIANCE; PNEUMOCOCCAL MENINGITIS; PNEUMOCYSTIS PNEUMONIA; PREDICTION; PREECLAMPSIA; PREGNANCY; PROSPECTIVE STUDY; SOUTH AFRICA; TERTIARY HEALTH CARE; TREATMENT OUTCOME; TUBERCULOSIS; URINARY TRACT INFECTION; VIRUS LOAD;

EID: 67650133524     PISSN: 00382329     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. National Department of Health. National Antiretroviral Treatment Guidelines. 1st ed. Pretoria: Jacana, 2004.
2. National Department of Health. Policy and Guidelines for the Implementation of the PMTCT Programme. South Africa 2008. Pretoria: National Department of Health, 2008. http://www.doh.gov.za/docs/ guidelines/pmtct.pdf (accessed 20 February 2008).
3. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22-29.
4. Dorrington RE, Johnson LF, Bradshaw D, Daniel T. The Demographic Impact of HIV/AIDS in South Africa. National and Provincial Indicators for 2006. Cape Town: Centre for Actuarial Research, South African Medical Research Council and Actuarial Society of South Africa, 2006.
5. National Department of Health. Saving Mothers. Third Report on Confidential Enquiries into Maternal Deaths in South Africa 2002-2004. Pretoria: Department of Health, 2006.
6. Statistics South Africa. Mortality and Causes of Death in South Africa, 2005: Findings from Death Notification. Pretoria: Statistics South Africa, 2007. www.statssa.org.za (accessed 28 April 2008).
7. Khan M, Pillay T, Moodley J, Connolly C. Maternal mortality associated with tuberculosis - HIV-1 co-infection in Durban, South Africa. AIDS 2001; 15(14): 1857-1863.
8. van der Merwe K, Chersich MF, Technau K, Umurungi Y, Conradie F, Coovadia A. Integration of antiretroviral treatment within antenatal care in Gauteng province, South Africa. J Acquir Immune Defic Syndr 2006; 43(5): 577-581.
9. National Department of Health. National HIV and Syphilis Antenatal Seroprevalence Survey in South Africa 2006. South Africa, 2007. Pretoria: Directorate: Health Systems Research, Research Coordination and Epidemiology, Department of Health, 2008. http://www.doh.gov.za (accessed 30 April 2008).
10. Besser M. Mothers 2 Mothers. South African Journal of Obstetrics and Gynaecology 2006; 12(3): 122-128.
11. Regensberg L, Whitelaw C. AfA Clinical Guidelines. 6th ed. Pinelands: Aid for AIDS, 2007: 26.
12. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19(4): 399-406.
13. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18(6): 887-895.
14. The DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - a Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Bethesda, Md: National Institutes of Health, 1 December 2007.
15. Badri M, Lawn SD, Wood R. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet 2006; 368: 1254-1259.
16. Lawn SD, Myer L, Bekker L, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21(3): 335-341.
17. Murdoch DM, Venter Willem DF, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008; 22(5): 601-610.
18. Lipman Marc CI, Carding SK. Successful drug treatment of immune reconstitution disease with the leukotriene receptor antagonist, montelukast: a clue to pathogenesis? AIDS 2007; 21(3): 383-384.
19. Park WB, Choe PG, Jo JH, et al. Immune reconstitution inflammatory syndrome in the first year after HAART: influence on long-term clinical outcome. AIDS 2006; 20(18): 2390-2392.
20. Kali PBN, Gray GE, Violari A, Chaisson RE, McIntyre JA, Martinson NA. Combining PMTCT with active case finding for tuberculosis. J Acquir Immune Defic Syndr 2006; 42(3): 379-381.
21. Public Health Service Task Force. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. 2 November 2007. http://AIDSinfo.nih.gov (accessed 30 April 2008).
22. National Department of Health. National 'DRAFT' Antiretroviral Treatment Guidelines. South Africa 2007. Pretoria: National Department of Health, 2008. http://www.doh.gov.za/docs/guidelines/ (accessed 19 November 2007).
23. Wade NA, Unadkat JD, Huang S, et al. Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group Protocol 332. J Infect Dis 2004; 190: 2167-2174.
24. Havlir DV, Tierney C, Friedland GH, et al. In vivo antagonism with zidovudine plus stavudine combination therapy. J Infect Dis 2000; 182: 321-325.
25. Back D, Gibbons S, Khoo S. Pharmacokinetic drug interactions with nevirapine. J Acquir Immune Defic Syndr 2003; 34(Suppl 1): S08-S14.
26. van Leth F, Andrews S, Grinsztejn B, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005; 19(5): 463-471.
27. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004; 35(5): 538-539.
28. Hitti J, Andersen J, McComsey G, et al. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol 2007; 196(4): 331-333.
29. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2007. Wilmington, NC: Registry Coordinating Center, 2007. www.APRegistry.com (accessed 30 April 2008).
30. Frank KA, Buchmann EJ, Schackis RC. Does human immunodeficiency virus infection protect against pre-eclampsia-eclampsia? Obstet Gynecol 2004; 104(2): 238-242.
31. Suy A, Martinez E, Coll O, et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 2006; 20: 59-66.
32. Tuomala RE, Watts DH, Li D, et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr 2005; 38(4): 449-473.
33. Boer K, Nellen JF, Patel D, et al. The AmRo study: pregnancy outcome in HIV-1-infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery. Br J Obstet Gynaecol 2007; 114: 148-155.
34. Walker JJ. Pre-eclampsia. Lancet 2000; 356: 1260-1265.
35. Rodrigues Vas MJ, Barros SMO, et al. HIV-infected pregnant women have greater adherence with antiretroviral drugs than non-pregnant women. Int J STD AIDS 2007; 18: 28-32.
36. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 2006; 43(1): 78-84.
37. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368: 505-510.